Using ORLA PDL-1 to save the world

使用 ORLA PDL-1 拯救世界

• 批准号: 103018
• 金额: $ 8.84万
• 依托单位: ORLA PROTEIN TECHNOLOGIES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103018
• 关键词: Using; ORLA; PDL; save; world

In the last few decades, drugs, biologicals, and vaccines targeting certain attributes of the immune system, known as immunotherapeutics, have become available, and emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer for years to come. Elimination of cancer by T-cells is only one step in the cancer immunity cycle. T-cell activation is controlled by both stimulatory and inhibitory checkpoints. Tumors use the expression of inhibitory ligands as a mechanism of suppressing cytotoxic T-cell response and inducing an immunosuppressive environment. Identification of specific cancer T-cell inhibitory signals, such as PD-L1, has prompted the development of a new class of cancer immunotherapy. Although immunotherapies represent a major step forward in cancer care, providing in some cases, unprecedented response rates, there are still major bottlenecks to be overcome in the manufacture of these new therapies. Orla Protein Technologies is an UK based biotechnology company that is attracting increasing market traction for its OrlaSURF platform in the biomanufacturing industry. This project will enable the company to utilize its proprietary platform to develop an innovative new range of engineered protein reagents to address key industry manufacturing needs.

在过去的几十年里，针对免疫系统某些属性的药物、生物制剂和疫苗（称为免疫治疗剂）已经上市，新出现的临床数据表明，癌症免疫治疗很可能成为未来几年癌症临床管理的关键部分。通过T细胞消除癌症只是癌症免疫周期中的一个步骤。T细胞活化受刺激性和抑制性检查点控制。肿瘤使用抑制性配体的表达作为抑制细胞毒性T细胞应答和诱导免疫抑制环境的机制。特定癌症T细胞抑制信号（例如PD-L1）的识别促进了一类新型癌症免疫疗法的开发。尽管免疫疗法代表了癌症治疗的一个重大进步，在某些情况下提供了前所未有的反应率，但在制造这些新疗法方面仍有重大瓶颈需要克服。Orla Protein Technologies是一家总部位于英国的生物技术公司，其OrlaSURF平台在生物制造行业的市场吸引力越来越大。该项目将使公司能够利用其专有平台开发一系列创新的工程蛋白试剂，以满足关键的行业制造需求。